Literature DB >> 31953603

Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.

Takaaki Tsuchiya1, Masanori Someya1, Yu Takada2, Tomokazu Hasegawa1, Mio Kitagawa1, Yuki Fukushima1, Toshio Gocho3, Masakazu Hori1, Kensei Nakata2, Yoshihiko Hirohashi4, Toshihiko Torigoe4, Tsuyoshi Saito5, Koh-Ichi Sakata6.   

Abstract

PURPOSE: To evaluate radiotherapy-induced changes in the expression of programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), and human leukocyte antigen class I (HLA-1) in patients with uterine cervical cancer, as well as infiltration of CD8+ and Forkhead box P3+ (FoxP3+) T lymphocytes into tumor tissue and the prognostic value of these parameters.
MATERIALS AND METHODS: We performed immunohistochemical analysis of pre-radiotherapy biopsies and corresponding post-radiotherapy resected tissues in 104 uterine cervical cancer patients undergoing preoperative chemoradiotherapy or radiotherapy alone. We scored the expression of various proteins to distinguish positive from negative samples.
RESULTS: PD-L1-expressing tumor cells (PD-L1 TC) increased significantly after chemoradiotherapy (p = 0.043). CD8+ T cell infiltration (p = 0.002) and FoxP3+ T cell infiltration (p = 0.003) decreased significantly after chemoradiotherapy. Expression of PD‑1, PD-L1-expressing immune cells (PD-L1 IC), and HLA‑1 did not change after chemoradiotherapy. In biopsy specimens obtained before chemoradiotherapy or radiotherapy, greater infiltration of CD8+ T cells (p = 0.001) and FoxP3+ T cells (p = 0.003) were significant predictors of better overall survival (OS). In surgical specimens obtained after chemoradiotherapy or radiotherapy, greater infiltration of PD-L1 TC was the only significant predictor of better OS (p < 0.001) and was related to a significantly lower probability of out-of-field recurrence (p = 0.005).
CONCLUSION: Chemoradiotherapy induced an immunologic shift that increased PD-L1 TC. Chemoradiotherapy has immunological effects that can influence the results of treatment for uterine cervical cancer.

Entities:  

Keywords:  CD8; Forkhead box P3; Human leukocyte antigen class I; Programmed cell death 1; Tumor immunity

Mesh:

Substances:

Year:  2020        PMID: 31953603     DOI: 10.1007/s00066-019-01571-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  11 in total

1.  Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.

Authors:  Yasumasa Mori; Hiro Sato; Takuya Kumazawa; Tiara Bunga Mayang Permata; Yuya Yoshimoto; Kazutoshi Murata; Shin-Ei Noda; Takuya Kaminuma; Ken Ando; Takahiro Oike; Noriyuki Okonogi; Kohei Okada; Sangeeta Kakoti; Keiji Suzuki; Hayato Ikota; Hideaki Yokoo; Takashi Nakano; Tatsuya Ohno; Atsushi Shibata
Journal:  Oncol Lett       Date:  2021-04-06       Impact factor: 2.967

2.  [Highlights from the 2021 ASCO and ESMO annual meetings on radiotherapy of head and neck cancer].

Authors:  Markus Hecht; Jens von der Grün; Sabine Semrau; Sarina Müller; Thomas Weissmann; Udo S Gaipl; Heinrich Iro; Rainer Fietkau; Antoniu-Oreste Gostian
Journal:  HNO       Date:  2022-03-16       Impact factor: 1.284

3.  Influence of chemoradiation on the immune microenvironment of cervical cancer patients.

Authors:  J M Herter; M Kiljan; S Kunze; M Reinscheid; O Ibruli; J Cai; L Niu; I Heßelmann; M Trommer; G S Herter-Sprie; C Köhler; S Marnitz
Journal:  Strahlenther Onkol       Date:  2022-10-17       Impact factor: 4.033

4.  Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.

Authors:  Masanori Someya; Takaaki Tsuchiya; Yuki Fukushima; Tomokazu Hasegawa; Masakazu Hori; Mio Kitagawa; Toshio Gocho; Shoh Mafune; Yutaro Ikeuchi; Yoshihiko Hirohashi; Toshihiko Torigoe; Masahiro Iwasaki; Motoki Matsuura; Tsuyoshi Saito; Yoshihisa Matsumoto; Koh-Ichi Sakata
Journal:  Med Mol Morphol       Date:  2021-05-08       Impact factor: 2.309

5.  Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.

Authors:  Chen Zhang; Qing Yang
Journal:  Front Oncol       Date:  2021-02-01       Impact factor: 6.244

6.  Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.

Authors:  Luisa Maria Griewing; Claudia Schweizer; Philipp Schubert; Sandra Rutzner; Markus Eckstein; Benjamin Frey; Marlen Haderlein; Thomas Weissmann; Sabine Semrau; Antoniu-Oreste Gostian; Sarina K Müller; Maximilian Traxdorf; Heinrich Iro; Jian-Guo Zhou; Udo S Gaipl; Rainer Fietkau; Markus Hecht
Journal:  BMC Cancer       Date:  2021-03-24       Impact factor: 4.430

Review 7.  The role of radiotherapy in the age of immunotherapy.

Authors:  Hiro Sato; Sandra Demaria; Tatsuya Ohno
Journal:  Jpn J Clin Oncol       Date:  2021-04-01       Impact factor: 3.019

8.  The Prognostic Value of FoxP3+ Tumour-Infiltrating Lymphocytes in Rectal Cancer Depends on Immune Phenotypes Defined by CD8+ Cytotoxic T Cell Density.

Authors:  Sören Schnellhardt; Johannes Hirneth; Maike Büttner-Herold; Christoph Daniel; Marlen Haderlein; Arndt Hartmann; Rainer Fietkau; Luitpold Distel
Journal:  Front Immunol       Date:  2022-01-24       Impact factor: 7.561

Review 9.  Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.

Authors:  Masanori Someya; Yuki Fukushima; Tomokazu Hasegawa; Takaaki Tsuchiya; Mio Kitagawa; Toshio Gocho; Shoh Mafune; Yutaro Ikeuchi; Yoh Kozuka; Yoshihiko Hirohashi; Toshihiko Torigoe; Masahiro Iwasaki; Motoki Matsuura; Tsuyoshi Saito; Koh-Ichi Sakata
Journal:  Jpn J Radiol       Date:  2022-01-01       Impact factor: 2.701

10.  Immune correlates of therapy outcomes in women with cervical cancer treated with chemoradiotherapy: A systematic review.

Authors:  David S Lakomy; Juliana Wu; Dorothy Lombe; Emmanouil Papasavvas; Susan Citonje Msadabwe; Yimin Geng; Luis J Montaner; Elizabeth Chiao; Lilie L Lin
Journal:  Cancer Med       Date:  2021-06-12       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.